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Abstract
Background: The anticancer TS-1® combination capsules of tegafur, gimeracil, and oteracil potassium (Taiho
Pharmaceutical Co. Ltd, Japan) causes side effects, i. e., corneal epithelial disorder and dacryostenosis. However, its
side effect on meibomian gland had not been reported. We observed morphological changes in the meibomian
gland in patients taking TS-1® who exhibited punctate corneal epithelial defects to examine if dysfunction of
meibomian glands is involved in the corneal epitheliopathy.
Case presentation: Patients comprised two males and one female (age, 59–81 years). After starting oral TS-1®
administration, patients developed subjective symptoms such as decreased visual acuity. Corneal epithelial disorder
was seen in all six eyes of the three subjects exhibited, and lacrimal duct disorder was seen in one eye.
Furthermore, meibomian gland loss and contraction were observed in all six eyes that exhibited meibomian gland
disorder upon examination by using the MeiboPen®.
Conclusions: Results suggested that oral administration of TS-1® may cause meibomian gland disorder which
potentially affect corneal epithelial homeostasis.
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Background
An anticancer combination capsules, TS-1® combination
capsules (Taiho Pharmaceutical Co. Ltd, Japan), contain
tegafur, a 5-fluorouracil (5-FU) prodrug; gimeracil, a 5-
FU decomposing enzyme inhibitor; and oteracil potas-
sium, which blocks 5-FU activation in the digestive tract,
thereby inhibiting the development of gastrointestinal
disorder. TS-1® is currently used for a wide range of ma-
lignant tumors, including gastric cancer, rectal cancer,
head and neck cancer, and lung cancer [1, 2].
5-FU is incorporated into RNA as a substitute for
uracil. The 5-FU metabolite fluorodeoxyuridine mono-
phosphate blocks DNA synthesis [3]. 5-FU exhibits anti-
tumor effects via these inhibitions of RNA function and
DNA synthesis; however, since it is also incorporated
into healthy cells along with tumor cells, it often causes
side effects in tissues with actively dividing cells [4].
Reported major side effects in ocular tissues include
corneal epithelial disorder, dacryoma, dacryostenosis,
and lacrimal duct obstruction, which are caused by 5-FU
transferred into lacrimal fluid. There are various types of
corneal epithelial disorders, including superficial punc-
tate keratopathy-like lesions and false branch-shaped le-
sions [5–7]. The existence of the lumen occlusive side
effects of dacryoma, dacryostenosis, and lacrimal duct
obstruction suggests that meibomian gland disorders
could also occur. These findings suggest that lacrimal
fluid containing 5-FU is secreted to the eye surface,
causing inflammation around orifice of the meibomian
gland. Such inflammation may subsequently have caused
keratinization and fibrosis, leading to obstruction of the
orifice of meibomian gland and resulting in meibomian
gland obstruction and subsequent tissue damage. How-
ever, there have been no detailed investigations pertain-
ing to the effects of TS-1® on the meibomian glands,
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which are an appendage of the surface of the eye. We
applied non-invasive mobile meibography (MeiboPen®;
Japan Focus Company Ltd., Tokyo, Japan) to patients
who had corneal epithelial disorders using TS-1® to ob-
serve morphological changes in meibomian glands and




A 59-year-old male patient underwent surgery for gall-
bladder cancer in June 2011. He was administered oral
TS-1® (100 mg/day) from August 2011, and after about
3 months, he started experiencing discomfort in both
eyes; he was examined at our department in July 2012.
He did not receive systemic and topical medications that
might cause tissue damage in the ocular surface. His vis-
ual acuity was 0.5 (0.8) in the right eye and 0.6 (0.8) in
the left eye. Intraocular pressure was 10 mmHg in both
eyes. Schirmer I test (with topical oxybuprocaine hydro-
chloride) did not show reduction of tear secretion
(26 mm for the right eye and 35 mm for the left eye).
Slit-lamp microscopy indicated punctate keratopathy-
like lesions in the cornea of both eyes (Fig. 1a, b). No
lacrimal punctum obstruction or lacrimal duct obstruc-
tion were observed. Observation of the meibomian
glands with the MeiboPen® revealed loss and contraction
of meibomian glands (white dotted line range). Meibo-
score was 6 in both eyes. While administration of TS-1®
was continued, diquafosol sodium eye drops were also
prescribed, and the patient’s course was observed. Con-
sequently, both corneas improved, as did the patient’s
subjective symptoms (Fig. 2a, b, c, d).
Case 2
An 81-year-old female underwent surgery for gingival
cancer in May 2012. Postoperatively, oral administration
of 80 mg/day of TS-1® was initiated, following which she
experienced blurred vision in both eyes and went to see
her regular physician. She was diagnosed with corneal
epithelial disorder and given additional treatment with
sodium hyaluronate eye drops. However, the corneal epi-
thelial disorder deteriorated, so she was referred to our
department in January 2013. She had already discontin-
ued TS-1® treatment when we examined her. She did not
receive systemic and topical medications that might
cause tissue damage in the ocular surface. Her visual
acuity was 0.06 (noncorrigunt) in the right eye and 0.04
(noncorrigunt) in the left eye. Intraocular pressure was
12 mmHg in the right eye and could not be measured in
the left eye. Schirmer I test (with topical oxybuprocaine
hydrochloride) showed reduction of tear secretion
(0 mm for both eyes). Slit-lamp microscopy indicated
corneal erosion near the central part of the cornea in
both eyes (Fig. 3a, b). No lacrimal punctum obstruction
or dacryostenosis were noted in either eye. Loss and
contraction of meibomian glands were observed. Meibo
score was 4 in the right eye and 4 in the left eye (Fig. 4a,
b, c, d). Rebamipide ophthalmic solution and ofloxacin
eye ointment were additionally prescribed and the pa-
tient was followed up regularly. Consequently, the cor-
neal condition improved, as did the patient’s subjective
symptoms.
Case 3
A 66-year-old male underwent surgery for gallbladder
cancer in July 2012. Oral administration of TS-1®
(80 mg/day) was initiated in August 2012, and approxi-
mately 2 months later, the patient experienced decreased
visual acuity in both eyes; he was examined at our de-
partment in January 2013. He did not receive systemic
and topical medications that might cause tissue damage
in the ocular surface. His visual acuity was 0.2 (0.3) in
the right eye and 0.15 (0.2) in the left eye. Intraocular
pressure was 20 mmHg in the right eye and 11 mmHg in
the left eye. Schirmer I test (with topical oxybuprocaine
Fig. 1 Case 1. Anterior segment photography. Superficial punctate keratopathy-like lesions observed in both eyes from the central to lower part
of the cornea. a: right eye, b: left eye
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hydrochloride) showed reduction of tear secretion (21 mm
for the right eye and 8 mm for the left eye). Slit-lamp mi-
croscopy indicated superficial punctate keratopathy-like
lesions in the corneas of both eyes. Lacrimal punctum nar-
rowing and lacrimal duct obstruction were observed in
the right eye only. Loss and contraction of meibomian
glands were observed, and meibo score was 4 for the right
eye and 3 for the left eye. Funduscopy indicated simple
diabetic retinopathy. However, TS-1® administration was
continued, and it was decided that the patient be regularly
followed up by his local physician.
Discussion
We observed meibomian gland loss and contraction in
all six eyes of patients taking TS-1® whom we examined
for meibomian gland disorders. Although meibo-score is
known to increase with age, the mean meibo score in
healthy individuals in their 50s to their 80s has been
reported as < 2 [8]. Meibo-scores for our patients
ranged 3 – 6. We thus consider that TS-1® might have
been responsible for meibomian gland abnormality. Cor-
neal epithelial disorder was observed in all three cases (six
eyes) examined in this study, and lacrimal duct disorder
was noted in one eye. The possible reason why the degree
of the damage differed aming each gland is to be clarified.
However, explanation might include the size the of the
duct affects the obstruction of the orifice of the gland.
A previous report of a pathological examination showed
that repeated administration of TS-1® induced focal necro-
sis, epithelial hyperplasia and neutrophilic inflammation
in conjunctival in dogs [10]. Incresead concentration of 5-
FU upon systemic administration of TS-1® causes obstruc-
tion of lacrymal apparatus [7]. These reports suggest that
5-FU in tear fluid might induce local inflammation
in/around orifice of the glands. This inflammation
may subsequently have caused keratinization and fibrosis,
Fig. 2 Case 1. Meibography. a, Upper right eyelid. Meibo score 3; b, Upper left eyelid. Meibo score: 3; c, Lower right eyelid. Meibo score: 3; d,
Lower left eyelid. Meibo score: 3. Dotted lines indicate the loss and contraction of meibomian glands zone
Fig. 3 Case 2. Anterior segment photography. a, right eye, b; left eye. Epithelial defects were noted near the central part of the cornea in
both eyes
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leading to obstruction of meibomian gland orifice and
resulting in meibomian gland obstruction and loss. A
manuscript is available that report on the meibomian
gland abnormality in patients with longstanding wearing
orbital prosthesis, suggesting that conjunctival persistent
subclinical inflammation might cause the phenomenon
[11]. This report also support the possibility that TS-1®
might damage the orifice of the meibomian gland.
Function of meibomian glands is considered to depend
on proliferation of its acinar cells. Cell proliferation is
mediated a set of variety of enzymes including thymidy-
late synthase of which expression is upregulated by vari-
ous growth factors. 5-FU is known to inhibit the activity
of this enzyme, leading to attenuation of cell growth. It
is to be examined if systemic TS-1® affects cell prolifera-
tion activity in meibomian glands in animal experiments.
Treatment may include (i) TS-1® discontinuation, (ii)
frequent use of artificial lacrimal fluid and dry eye treat-
ment with sodium hyaluronate eye drops to wash out
TS-1® in lacrimal fluid and protect the corneas, (iii) use
of antibiotics to prevent infection in cases of corneal epi-
thelium loss, and (iv) if dacryostenosis is suspected, lac-
rimal punctum incision or silicon tube placement. It has
also been reported that symptoms improved in cases of
persistent corneal epithelial disorder persists after cessa-
tion of TS-1®. Topical treatment for the damage in the
corneal epithelium in Cases 1 and 2 was considered to
be effective presumably due to direct effects on the cor-
neal epithelial homeostasis, but not on the meibomian
glands. Administration with autologous serum eye drops
[12], a hot compress, a conventional treatment for mei-
bomian gland dysfunction, and lid hygiene may not only
improve meibomian gland function, but also alleviate
symptoms of corneal epithelial disorder.
In the current manuscript we report meibomian gland
abnormality in patients with TS-1® administration. The
finding here prompts us to plan not only a retrospective
survey but also a prospective study to examine the ef-
fects of TS-1® on meibomian gland morphology and
function.
Conclusions
Oral administration of TS-1® might cause meibomian
gland disorder which potentially affect corneal epithelial
homeostasis. Further study is needed to uncover the side
effects of TS-1® on meibomian gland morphology and
function.
Consent
This study was performed in accordance with the
Helsinki Declaration. Written informed consent were
obtained from all three patients for publication of this
Case report and any accompanying images. The copys of




Fig. 4 Case 2. Meibography. a, Upper right eyelid. Meibo score: 1; b, Upper left eyelid. Meibo score: 1; c, Lower right eyelid. Meibo score: 3; d,
Lower left eyelid. Meibo score: 3. Dotted lines indicate the loss and contraction of meibomian glands zone
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